LT3363438T - Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių - Google Patents

Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių

Info

Publication number
LT3363438T
LT3363438T LT17206491T LT17206491T LT3363438T LT 3363438 T LT3363438 T LT 3363438T LT 17206491 T LT17206491 T LT 17206491T LT 17206491 T LT17206491 T LT 17206491T LT 3363438 T LT3363438 T LT 3363438T
Authority
LT
Lithuania
Prior art keywords
orexine
azabicycles
modified
receptor modulators
modulators
Prior art date
Application number
LT17206491T
Other languages
English (en)
Inventor
Christine F Gelin
Terry P Lebold
Brock T Shireman
Jeannie M Ziff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LT3363438T publication Critical patent/LT3363438T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LT17206491T 2013-03-13 2014-03-12 Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių LT3363438T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
LT3363438T true LT3363438T (lt) 2019-11-11

Family

ID=50487148

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14717576.4T LT2970314T (lt) 2013-03-13 2014-03-12 Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptoriaus moduliatorių
LT17206491T LT3363438T (lt) 2013-03-13 2014-03-12 Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14717576.4T LT2970314T (lt) 2013-03-13 2014-03-12 Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptoriaus moduliatorių

Country Status (38)

Country Link
US (5) US9611277B2 (lt)
EP (4) EP3622956B9 (lt)
JP (1) JP6275815B2 (lt)
KR (1) KR102209424B1 (lt)
CN (3) CN105308048B (lt)
AR (1) AR095423A1 (lt)
AU (2) AU2014248680B2 (lt)
BR (1) BR112015022294B1 (lt)
CA (1) CA2904618C (lt)
CL (1) CL2015002609A1 (lt)
CR (2) CR20210523A (lt)
CY (3) CY1120024T1 (lt)
DK (2) DK2970314T3 (lt)
EA (1) EA029276B1 (lt)
ES (3) ES2760564T3 (lt)
HR (3) HRP20180303T1 (lt)
HU (3) HUE063608T2 (lt)
IL (2) IL240466B (lt)
JO (1) JOP20140092B1 (lt)
LT (2) LT2970314T (lt)
ME (2) ME03011B (lt)
MX (2) MX368466B (lt)
MY (1) MY183725A (lt)
NI (1) NI201500130A (lt)
NO (1) NO3107630T3 (lt)
PE (1) PE20151599A1 (lt)
PH (1) PH12015501929B1 (lt)
PL (3) PL2970314T3 (lt)
PT (2) PT3363438T (lt)
RS (3) RS56875B1 (lt)
SG (1) SG11201507415QA (lt)
SI (2) SI2970314T1 (lt)
SM (3) SMT201800056T1 (lt)
TW (1) TWI621618B (lt)
UA (1) UA118669C2 (lt)
UY (1) UY35409A (lt)
WO (1) WO2014165070A1 (lt)
ZA (1) ZA201507562B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
AU2015226679B2 (en) 2014-03-06 2017-05-25 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Piperidine derivatives as orexin receptor antagonist
WO2016040789A1 (en) * 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN107709318B (zh) * 2015-08-14 2020-09-25 上海海雁医药科技有限公司 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
RS63296B1 (sr) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Metode lečenja depresije korišćenjem antagonista receptora oreksin-2
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
SMT202500122T1 (it) 2017-09-01 2025-05-12 Chronos Therapeutics Ltd Derivati di 2-azabiciclo[3.1.1]eptano e 2-azabiciclo[3.2.1]ottano sostituiti come antagonisti del recettore di oressina
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CA3115126A1 (en) * 2018-12-14 2020-06-18 Nathanael S. Gray Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
AU2003202753A1 (en) 2003-02-07 2004-08-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
MXPA05008108A (es) 2003-02-21 2005-09-21 Pharmacia & Upjohn Co Llc Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
KR20080076962A (ko) 2005-12-20 2008-08-20 노파르티스 아게 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체
MX2009002684A (es) 2006-09-11 2009-06-05 Novartis Ag Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
JP2010528007A (ja) * 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
CN101965343A (zh) * 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物
WO2009133522A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
EP2318404B1 (en) 2008-07-16 2013-08-21 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9546152B2 (en) 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CA2938719A1 (en) 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
WO2016040789A1 (en) 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
AU2018204835A1 (en) 2018-07-19
PT3363438T (pt) 2019-12-11
KR20150126694A (ko) 2015-11-12
PH12015501929A1 (en) 2016-01-04
CN105308048A (zh) 2016-02-03
DK3363438T3 (da) 2019-11-11
EP3363438A1 (en) 2018-08-22
MX2015011815A (es) 2016-11-07
UA118669C2 (uk) 2019-02-25
US20170015651A1 (en) 2017-01-19
DK2970314T3 (en) 2018-02-26
CR20150433A (es) 2015-10-26
HUE047592T2 (hu) 2020-05-28
UY35409A (es) 2014-09-30
MX361529B (es) 2018-12-07
EP3622956A1 (en) 2020-03-18
CL2015002609A1 (es) 2016-03-28
SMT201900655T1 (it) 2020-01-14
US20170204096A1 (en) 2017-07-20
RS59466B1 (sr) 2019-11-29
SI3363438T1 (sl) 2019-11-29
SG11201507415QA (en) 2015-10-29
NI201500130A (es) 2015-11-30
AU2018204835B2 (en) 2019-08-08
AU2014248680B2 (en) 2018-07-26
MY183725A (en) 2021-03-10
NZ710872A (en) 2020-10-30
BR112015022294B1 (pt) 2022-09-13
CN110669052A (zh) 2020-01-10
EP3622956B1 (en) 2023-06-07
EP2970314B1 (en) 2017-12-13
PL2970314T3 (pl) 2018-05-30
HUE063608T2 (hu) 2024-01-28
EP3622956B9 (en) 2023-09-27
EP3363438B1 (en) 2019-09-18
TWI621618B (zh) 2018-04-21
PL3363438T3 (pl) 2020-02-28
CN105308048B (zh) 2019-10-08
PT2970314T (pt) 2018-03-05
SMT201800056T1 (it) 2018-03-08
JP6275815B2 (ja) 2018-02-07
ZA201507562B (en) 2019-04-24
SI2970314T1 (en) 2018-02-28
AR095423A1 (es) 2015-10-14
ES2950032T3 (es) 2023-10-04
AU2014248680A1 (en) 2015-08-27
CN110669052B (zh) 2022-10-11
LT2970314T (lt) 2018-02-12
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
IL264606A (en) 2019-02-28
US9447117B2 (en) 2016-09-20
RS56875B1 (sr) 2018-04-30
CN108864093A (zh) 2018-11-23
EA029276B1 (ru) 2018-03-30
JP2016512535A (ja) 2016-04-28
MX368466B (es) 2019-10-03
CA2904618A1 (en) 2014-10-09
PH12015501929B1 (en) 2016-01-04
RS64551B9 (sr) 2023-12-29
US10183953B2 (en) 2019-01-22
JOP20140092B1 (ar) 2021-08-17
BR112015022294A2 (pt) 2017-07-18
NO3107630T3 (lt) 2018-01-06
HUE036193T2 (hu) 2018-06-28
SMT202300223T1 (it) 2023-09-06
EP4272824A2 (en) 2023-11-08
CY1120024T1 (el) 2018-12-12
HRP20180303T1 (hr) 2018-03-23
IL240466A0 (en) 2015-09-24
US20140275118A1 (en) 2014-09-18
CY1126106T1 (el) 2023-11-15
PE20151599A1 (es) 2015-11-12
IL240466B (en) 2019-03-31
HRP20230633T1 (hr) 2023-09-29
PL3622956T3 (pl) 2023-09-18
ES2760564T3 (es) 2020-05-14
TW201446757A (zh) 2014-12-16
CY1122392T1 (el) 2021-01-27
HK1219725A1 (en) 2017-04-13
ES2659397T3 (es) 2018-03-15
CR20210523A (es) 2021-11-19
US9611277B2 (en) 2017-04-04
CA2904618C (en) 2021-12-07
US8969352B2 (en) 2015-03-03
WO2014165070A1 (en) 2014-10-09
ME03572B (me) 2020-07-20
US20160052939A1 (en) 2016-02-25
EP4272824A3 (en) 2024-01-10
US20150174129A1 (en) 2015-06-25
ME03011B (me) 2018-10-20
US9845333B2 (en) 2017-12-19
KR102209424B1 (ko) 2021-01-29
HRP20192032T1 (hr) 2020-02-07
RS64551B1 (sr) 2023-10-31
EP3622956C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
LT3363438T (lt) Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių
DK3848027T3 (da) Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
LT3192812T (lt) Anti-cd3 antikūnai ir jų panaudojimo būdai
LT3071597T (lt) Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
DK2951183T3 (da) Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
IL240929B (en) 7- Converted azabicycles and their use as orexin receptor modulators
FR3014828B1 (fr) Trottinette motorisee
LT3003039T (lt) Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
DK3089765T3 (da) Biomedicinsk indretning
DK3053119T3 (da) Papirløs anvendelse
LT3030519T (lt) Tricikliniai benzoksaborolo junginiai ir jų naudojimas
LT3319963T (lt) Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
IL243728B (en) Indole derivatives as rorc2 inhibitors and uses thereof
LT3060660T (lt) Rekombinantiniai glikoproteinai ir jų naudojimas
IL240177A0 (en) Converted chromium-6-yloxy-cycloalkanes and their use as drugs
FR3007291B1 (fr) Composition cicatrisante et utlisation
EP3013851A4 (en) MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE
TH1501003524A (th) เม็ดสี